רווח למניה בשנים עשר החודשים האחרונים: Delcath Systems Inc (DCTH)

Due to its monopoly position in the treatment of metastatic melanoma, Delcath Systems, Inc. (DCTH) possesses significant pricing power. The 12-month net income per share history illustrates the dynamics of this process, where 0.15 captures a new level. The company leverages physician confidence in its unique liver perfusion system, scaling the business through the sale of high-margin consumables.

Delcath Systems, Inc. (DCTH) transition toward the commercialization of the HEPZATO KIT system shifts the company from the clinical development stage to a phase of real revenue generation. The TTM net income per share captures the total annual financial result distributed across all outstanding shares, allowing investors to assess the business's actual viability and expansion rates while filtering out market noise through the analysis of this chart.